Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Ferring Pharmaceuticals
Woman and Man Max 99 years
Ferring Pharmaceuticals A/S
Update Il y a 4 ans
A randomised, assessor-blinded, multi-centre trial comparing the efficacy, safety and tolerability of the PICOPREP tailored dosing schedule to the PICOPREP day-before dosing schedule for colon cleansing in preparation for colonoscopy
To demonstrate non-inferiority of a tailored PICOPREP dosing schedule compared to the day-before PICOPREP dosing schedule in overall colon cleansing in preparation for colonoscopy
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Ferring Pharmaceuticals A/S
Update Il y a 4 ans
A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk, who require neoadjuvant hormone therapy prior to radiotherapy (curative intent)
To demonstrate that the mean percentage reduction in prostate volume with degarelix is non-inferior to goserelin plus bicalutamide, based on a trans-rectal ultrasound scan (TRUS) at 12 weeks (Visit 5=...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Ferring Pharmaceuticals A/S
Update Il y a 4 ans
A randomised, open-label, assessor-blind, parallel groups, multicentre trial comparing the efficacy of MENOPUR versus recombinant FSH in controlled ovarian stimulation following a GnRH antagonist protocol and single embryo transfer
To compare MENOPUR and a recombinant FSH preparation with respect to pregnancy rates in women undergoing controlled ovarian stimulation following a GnRH antagonist protocol
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Ferring Pharmaceuticals A/S
Update Il y a 4 ans
A controlled, assessor-blind, parallel groups, multicentre, multinational trial evaluating the immunogenicity of FE 999049 in repeated cycles of controlled ovarian stimulation in women undergoing an assisted reproductive technology programme
To evaluate the immunogenicity of FE 999049 and GONAL-F based on the presence of anti-FSH antibodies and their neutralising capacity in women undergoing repeated controlled ovarian stimulation cycles
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Ferring Pharmaceuticals A/S
Update Il y a 4 ans
Estudio randomizado, doble ciego, de grupos paralelos, controlado con placebo, multicéntrico en donantes de oocitos que evalúa los efectos del barusiban, un antagonista selectivo de la oxitocina, sobre las contracciones uterinas el día que se transfiere el embrión al útero
Evaluar los efectos del barusiban comparados con placebo sobre las contracciones uterinas el día de la transferencia del embrión
Country
None
organs
None
Specialty
None
Closed trial
More information
Man
Between 18 years
and 99 years
Ferring Pharmaceuticals
Update Il y a 4 ans
FERRING FE200486 CS30 : Essai de phase 3 randomisé comparant l’efficacité du dégarelix à une hormonothérapie par gosérélin et bicalutamide, en traitement néo-adjuvant à une radiothérapie, chez des patients ayant un cancer de la prostate. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients of i...
Country
France
organs
Prostate
Specialty
Hormonothérapie
Essai clos aux inclusions
More information
Man Max 99 years
Ferring Pharmaceuticals A/S
Update Il y a 4 ans
A single-centre, open-label, randomised explorative pharmacokinetic/pharmacodynamic study of the gonadotropin-releasing hormone receptor antagonist degarelix (FE 200486) in patients with benign prostatic hyperplasia
To explore the pharmakokinetic/pharmacodynamic relationships at different doses of degarelix in benign prostatic hyperplasia (BPH) patients and to select doses and dosing regime for Phase II efficacy ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Ferring Pharmaceuticals A/S
Update Il y a 4 ans
An Open-Label, Multi-Centre, Randomised Parallel Group Comparison of Efficacy and Safety of Degarelix Three-Month Depot in Three Different Dosing Regimens of 240 mg (40 mg/mL) and 240 mg (60 mg/mL) in Patients with Prostate Cancer Requiring Androgen Ablation Therapy
•To demonstrate that the efficacy in achieving and maintaining testosterone castration levels (<=0.5 ng/mL) in prostate cancer patients treated up to either 12 or 13 months is at least 80%.
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Ferring Pharmaceuticals A/S
Update Il y a 4 ans
An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Ablation Therapy
To demonstrate efficacy of degarelix in achieving and maintaining testosterone suppression at castrate levels (≤0.5 ng/mL) during one year of treatment in prostate cancer patients.
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Ferring Pharmaceuticals A/S
Update Il y a 4 ans
An Open-label, Multi-Centre, Randomized, Parallel-group Study, Investigating the Efficacy and Safety of Degarelix One Month Dosing Regimens; 160 mg (40 mg/ml) and 80 mg (20mg/ml), in Comparison to LUPRON DEPOT® 7.5 mg in Patients with Prostate Cancer Requiring Androgen Ablation Therapy
Primary objective: •To demonstrate non-inferiority with respect to the proportion of patients achieving and maintaining testosterone suppression to castrate levels using a degarelix dosing regimen co...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
Next